TransCode Therapeutics Inc. (RNAZ) - Multiplikator forward rega marang pendapatan
RNA therapy developments for cancer treatment are currently in the testing phase, with financial stability sustained solely by shareholder investments. TransCode Therapeutics (RNAZ) is creating innovative methods for delivering molecules into tumors for future monetization through patents. The absence of commercial products and high R&D expenditures render cash flow unpredictable. The forward P/S multiple reflects the market's reaction to forecasts, where the mark captures this metric.
Rincian metrik komprehensif lan analitis transcodetherapeutics.com (RNAZ)
- rega saham lan target rega konsensus:
- indikator kapitalisasi pasar:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas TransCode Therapeutics|RNAZ - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal TransCode Therapeutics, Inc.|RNAZ - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku TransCode Therapeutics|RNAZ - Kewajiban jangka dawa|Utang jangka cendhak perusahaan TransCode Therapeutics|Indikator likuiditas cepet transcodetherapeutics.com
- rincian asil keuangan lan kelipatan valuasi:
RNAZ - Bathi resik|Bathi mangsa ngarep TransCode Therapeutics|RNAZ - Rasio rega pasar marang bathi resik|Pangali Forward P/E TransCode Therapeutics, Inc.|RNAZ - Kapitalisasi marang bathi resik kanthi nimbang wutah|Pangali EV/EBITDA TransCode Therapeutics|RNAZ - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan TransCode Therapeutics|RNAZ - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan transcodetherapeutics.com|RNAZ - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep TransCode Therapeutics
- statistik dodolan lan pendapatan perusahaan:
Analisis fundamental perusahaan:RNAZ (TransCode)
Forward P/S measures the market value of a business relative to projected sales volume, allowing for an objective assessment of capitalization adequacy for potential M&A transactions. Analyzing the projected price-to-sales ratio helps investors avoid overpaying, which is critical for TransCode Therapeutics (RNAZ), whose unique nanotransporters in oncology create high added value and protect the company from competitive pricing pressure.
Pesaing langsung
Tempus AI, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QGEN|IONS: Multiplikator forward rega marang pendapatan|Repligen Inc. - Rasio rega marang pendapatan sing dikarepake|RNA: Multiplikator Forward P/S|crisprtx.com - Rega forward marang dodolan|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Corp) - Rega forward marang dodolan|Multiplikator Forward P/S TWST (Twist Bioscience)|Multiplikator Forward P/S 10xgenomics.com TXG|NTLA - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan STOK|BLFS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Wave Pharma (WVE)|Multiplikator forward rega marang pendapatan MAZE|Multiplikator Forward P/S sionnatx.com|Multiplikator forward rega marang pendapatan PRME (Prime Medicine)|Rasio rega marang pendapatan sing dikarepake TSHA|Multiplikator Forward P/S QURE (uniQure Corp)|Rasio kapitalisasi marang dodolan sing dikarepake MeiraGTx Corp (MGTX)|REGENXBIO Inc. - Multiplikator Forward P/S|solidbio.com (SLDB) - Multiplikator forward rega marang pendapatan|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|PACB - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Benitec|DSGN: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S LXEO (Lexeo Therapeutics, Inc.)|Multiplikator Forward P/S Korro Bio Inc. KRRO|EDIT: Multiplikator forward rega marang pendapatan|Rega mangsa ngarep marang pendapatan SLN|PRQR: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan CDXS|Rasio rega marang prakiraan pendapatan Sangamo Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan NAUT (Nautilus Biotechnology Inc)|Multiplikator Forward P/S MGX|Multiplikator Forward P/S Precision BioSciences Inc. (DTIL)|Generation Bio - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake BOLD (boundlessbio.com)|XCUR - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan IMNN (Imunon, Inc.)|PHIO: Multiplikator Forward P/S|Mustang Bio (MBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|Kapitalisasi marang prakiraan pendapatan APDN (adnas.com)|Rasio rega marang prakiraan pendapatan bluebird bio (BLUE)|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Multiplikator Forward P/S OMGA (Omega)|OMIC - Multiplikator forward rega marang pendapatan|RGLS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep syros.com|TBIO: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan TCON|UBX (Unity Bio) - Multiplikator Forward P/S
